JP4743463B2 - 神経栄養置換ピリミジン - Google Patents
神経栄養置換ピリミジン Download PDFInfo
- Publication number
- JP4743463B2 JP4743463B2 JP2000610837A JP2000610837A JP4743463B2 JP 4743463 B2 JP4743463 B2 JP 4743463B2 JP 2000610837 A JP2000610837 A JP 2000610837A JP 2000610837 A JP2000610837 A JP 2000610837A JP 4743463 B2 JP4743463 B2 JP 4743463B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- amino
- pyrimidine
- aryl
- chlorophenoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *C(C(N1)=O)=C(*)N=C1S Chemical compound *C(C(N1)=O)=C(*)N=C1S 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N c1ccccc1 Chemical compound c1ccccc1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/288,495 | 1999-04-08 | ||
| US09/288,495 US6583148B1 (en) | 1999-04-08 | 1999-04-08 | Neurotrophic substituted pyrimidines |
| PCT/US2000/009108 WO2000061562A1 (en) | 1999-04-08 | 2000-04-06 | Neurotrophic substituted pyrimidines |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002541245A JP2002541245A (ja) | 2002-12-03 |
| JP2002541245A5 JP2002541245A5 (https=) | 2011-02-10 |
| JP4743463B2 true JP4743463B2 (ja) | 2011-08-10 |
Family
ID=23107364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000610837A Expired - Fee Related JP4743463B2 (ja) | 1999-04-08 | 2000-04-06 | 神経栄養置換ピリミジン |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US6583148B1 (https=) |
| EP (1) | EP1165523B1 (https=) |
| JP (1) | JP4743463B2 (https=) |
| AT (1) | ATE377592T1 (https=) |
| AU (1) | AU4331400A (https=) |
| CA (1) | CA2368843C (https=) |
| DE (1) | DE60037013T2 (https=) |
| WO (1) | WO2000061562A1 (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1303495T3 (da) * | 2000-07-24 | 2010-09-20 | Krenitsky Pharmaceuticals Inc | Substituerede 5-alkylnylpyrimidiner med neurotrofisk aktivitet |
| KR100608414B1 (ko) | 2002-02-13 | 2006-08-02 | 에프. 호프만-라 로슈 아게 | 신규한 피리딘- 및 피리미딘-유도체 |
| JP2005232081A (ja) * | 2004-02-19 | 2005-09-02 | Bayer Cropscience Ag | ベンジルピリミジン誘導体の農園芸用殺菌剤としての利用 |
| CN1930135B (zh) * | 2004-03-05 | 2011-12-28 | 弗·哈夫曼-拉罗切有限公司 | 作为p2x3和p2x2/3拮抗剂的二氨基嘧啶 |
| EP1871420A4 (en) * | 2005-04-15 | 2010-09-22 | Univ North Carolina | PROCESS FOR ENABLING CELL SURVIVAL VIA NEUROTROPHINE MIMETICS |
| US20110230479A1 (en) * | 2005-04-15 | 2011-09-22 | Longo Frank M | Neurotrophin mimetics and uses thereof |
| WO2006133353A2 (en) | 2005-06-08 | 2006-12-14 | The University Of North Carolina At Chapel Hill | Methods of facilitating neural cell survival using non-peptide and peptide bdnf neurotrophin mimetics |
| CA2620129C (en) | 2005-09-01 | 2014-12-23 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
| JP4850914B2 (ja) * | 2005-09-01 | 2012-01-11 | エフ．ホフマン−ラ ロシュ アーゲー | Ｐ２ｘ３およびｐ２ｘ２／３モジュレーターとしてのジアミノピリミジン |
| WO2007025900A1 (en) * | 2005-09-01 | 2007-03-08 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p3x2/3 modulators |
| CA2619919C (en) * | 2005-09-01 | 2014-04-01 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
| US9150507B2 (en) | 2006-04-28 | 2015-10-06 | Shionogi & Co., Ltd. | Amine derivative having NPY Y5 receptor antagonistic activity |
| RU2433119C2 (ru) * | 2006-04-28 | 2011-11-10 | Шионоги Энд Ко., Лтд. | Производное амина, обладающее антагонистической активностью в отношении рецептора npy y5 |
| CN101479238B (zh) * | 2006-04-28 | 2013-08-21 | 盐野义制药株式会社 | 具有npyy5受体拮抗活性的胺衍生物 |
| SA08290668B1 (ar) | 2007-10-25 | 2012-02-12 | شيونوجي آند كو.، ليمتد | مشتقات أمين لها نشاط مضاد لمستقبل npy y5 واستخداماتها |
| US8227618B2 (en) | 2009-04-23 | 2012-07-24 | Shionogi & Co., Ltd. | Amine-derivatives having NPY Y5 receptor antagonistic activity and the uses thereof |
| US10273219B2 (en) | 2009-11-12 | 2019-04-30 | Pharmatrophix, Inc. | Crystalline forms of neurotrophin mimetic compounds and their salts |
| ES2712752T3 (es) | 2009-11-12 | 2019-05-14 | Pharmatrophix Inc | Formas cristalinas de compuestos miméticos de neurotrofina y sus sales |
| HUE055286T2 (hu) | 2011-04-08 | 2021-11-29 | Janssen Sciences Ireland Unlimited Co | Pirimidinszármazékok vírusfertõzések kezelésére |
| RS57851B1 (sr) | 2011-11-09 | 2018-12-31 | Janssen Sciences Ireland Uc | Purinski derivati za tretman viralnih infekcija |
| CA2874800C (en) | 2012-07-13 | 2021-04-06 | Janssen R&D Ireland | Macrocyclic purines for the treatment of viral infections |
| CN104781239B (zh) * | 2012-08-10 | 2019-03-01 | 爱尔兰詹森科学公司 | 用于治疗病毒感染和另外的疾病的烷基嘧啶衍生物 |
| LT2906563T (lt) | 2012-10-10 | 2018-06-11 | Janssen Sciences Ireland Uc | Pirolo[3,2-d]pirimidino dariniai virusinių infekcijų ir kitų ligų gydymui |
| EP2925729B1 (en) | 2012-11-16 | 2017-10-18 | Janssen Sciences Ireland UC | Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections |
| WO2014128189A1 (en) | 2013-02-21 | 2014-08-28 | Janssen R&D Ireland | 2-aminopyrimidine derivatives for the treatment of viral infections |
| JP2016519668A (ja) | 2013-03-15 | 2016-07-07 | ファーマトロフィックス， インコーポレイテッド | 非ペプチドｂｄｎｆニューロトロフィン模倣化合物 |
| RU2015141934A (ru) | 2013-03-15 | 2017-04-20 | Фарматрофикс, Инк. | Непептидные миметики нейротрофина bdnf |
| AU2014242954B2 (en) | 2013-03-29 | 2018-03-15 | Janssen Sciences Ireland Uc | Macrocyclic deaza-purinones for the treatment of viral infections |
| SG11201509520QA (en) | 2013-05-24 | 2015-12-30 | Janssen Sciences Ireland Uc | Pyridone derivatives for the treatment of viral infections and further diseases |
| BR112015032546B1 (pt) | 2013-06-27 | 2022-05-17 | Janssen Sciences Ireland Uc | Derivados de pirrolo[3,2-d]pirimidina e composição farmacêutica que os compreende para o tratamento de infecções virais e outras doenças |
| KR102322425B1 (ko) | 2013-07-30 | 2021-11-05 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 바이러스 감염의 치료를 위한 티에노[3,2-d]피리미딘 유도체 |
| AU2017289418B2 (en) | 2016-07-01 | 2021-06-03 | Janssen Sciences Ireland Unlimited Company | Dihydropyranopyrimidines for the treatment of viral infections |
| JP7274415B2 (ja) | 2016-09-29 | 2023-05-16 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | ウイルス感染症および他の疾患を処置するためのピリミジンプロドラッグ |
| TW202415645A (zh) | 2018-03-01 | 2024-04-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | ２，４－二胺基喹唑啉衍生物及其醫學用途 |
| SG11202101085PA (en) | 2018-08-27 | 2021-03-30 | Sumitomo Dainippon Pharma Co Ltd | Optically active azabicyclic derivative |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2691655A (en) | 1952-05-24 | 1954-10-12 | Burroughs Wellcome Co | 2-amino-4-substituted amino-6-aryl pyrimidines and process of preparing same |
| GB951432A (en) | 1959-03-17 | 1964-03-04 | Wellcome Found | Pyrimidine derivatives and the manufacture thereof |
| US3862190A (en) | 1972-09-08 | 1975-01-21 | Pfizer | 5-(unsubstituted and substituted phenoxy)-4-amino pyrimidines |
| DK397574A (https=) * | 1973-08-24 | 1975-04-28 | Ciba Geigy Ag | |
| GB1523274A (en) | 1974-08-05 | 1978-08-31 | Ici Ltd | Herbicidal compositions containing substituted pyrimidine |
| FR2358148A1 (fr) | 1976-07-12 | 1978-02-10 | Dick Pr | Derives de 2,4-diaminopyrimidines et leur mise en solution en association avec des sulfamides |
| FR2397407A2 (fr) | 1977-07-11 | 1979-02-09 | Dick Pierre | Derives de 2,4-diamino pyrimidines et leur mise en solution en association avec des sulfamides |
| FI895821A7 (fi) | 1988-12-07 | 1990-06-08 | The Wellcome Foundation Ltd | Farmaseuttisesti aktivisia CNS-yhdisteitä |
| GB9012316D0 (en) | 1990-06-01 | 1990-07-18 | Wellcome Found | Pharmacologically active cns compounds |
| IE912114A1 (en) | 1990-07-02 | 1992-01-15 | Union Pharma Scient Appl | Novel pyrimidine derivatives which are angiotensin ii¹receptor antagonists, their methods of preparation and¹pharmaceutical compositions in which they are present |
| US5075305A (en) | 1991-03-18 | 1991-12-24 | Warner-Lambert Company | Compound, composition and use |
| FI934565A7 (fi) | 1991-04-17 | 1993-10-15 | Pfizer | Pyrimidiinijohdannaisia kasvaimenvastaisen vaikutuksen lisäämiseksi |
| US5336677A (en) | 1991-10-24 | 1994-08-09 | American Home Products Corporation | Substituted aminopyrimidines as antihypertensives |
| GB9125842D0 (en) | 1991-12-04 | 1992-02-05 | Ici Plc | Heterocyclic derivatives |
| WO1994014780A1 (en) | 1992-12-18 | 1994-07-07 | The Wellcome Foundation Limited | Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors |
| EP0640599B1 (en) | 1993-08-26 | 1998-03-04 | Ono Pharmaceutical Co., Ltd. | 4-Aminopyrimidine derivatives |
| JPH08283246A (ja) | 1994-06-01 | 1996-10-29 | Nippon Soda Co Ltd | ピリミジン誘導体、その製造方法及び有害生物防除剤 |
| CA2217034A1 (en) | 1995-04-03 | 1996-10-10 | Sumitomo Pharmaceuticals Company, Limited | Novel pyrimidine derivatives effective as psychotropic drug and process for the production thereof |
| US6440965B1 (en) | 1997-10-15 | 2002-08-27 | Krenitsky Pharmaceuticals, Inc. | Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system |
-
1999
- 1999-04-08 US US09/288,495 patent/US6583148B1/en not_active Expired - Fee Related
-
2000
- 2000-04-06 CA CA002368843A patent/CA2368843C/en not_active Expired - Fee Related
- 2000-04-06 AU AU43314/00A patent/AU4331400A/en not_active Abandoned
- 2000-04-06 JP JP2000610837A patent/JP4743463B2/ja not_active Expired - Fee Related
- 2000-04-06 AT AT00923138T patent/ATE377592T1/de not_active IP Right Cessation
- 2000-04-06 EP EP00923138A patent/EP1165523B1/en not_active Expired - Lifetime
- 2000-04-06 US US09/958,511 patent/US6916820B1/en not_active Expired - Fee Related
- 2000-04-06 DE DE60037013T patent/DE60037013T2/de not_active Expired - Lifetime
- 2000-04-06 WO PCT/US2000/009108 patent/WO2000061562A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CA2368843C (en) | 2009-10-20 |
| ATE377592T1 (de) | 2007-11-15 |
| JP2002541245A (ja) | 2002-12-03 |
| CA2368843A1 (en) | 2000-10-19 |
| WO2000061562A1 (en) | 2000-10-19 |
| US6916820B1 (en) | 2005-07-12 |
| AU4331400A (en) | 2000-11-14 |
| US6583148B1 (en) | 2003-06-24 |
| DE60037013T2 (de) | 2008-08-21 |
| DE60037013D1 (de) | 2007-12-20 |
| EP1165523A1 (en) | 2002-01-02 |
| EP1165523B1 (en) | 2007-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4743463B2 (ja) | 神経栄養置換ピリミジン | |
| US7205297B2 (en) | Substituted 5-alkynyl pyrimidines having neurotrophic activity | |
| US6440965B1 (en) | Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system | |
| US5712276A (en) | 2-(n-alkylpiperazino or morpholino)-4-amino-5-aryl-pyrimidines | |
| US8841315B2 (en) | Inhibitors of protein kinases | |
| EP0781766B1 (en) | Heterocyclic derivative and medicine | |
| US5589477A (en) | Pyrimidine derivatives and drugs | |
| EP1165522A1 (en) | Neurotrophic thio substituted pyrimidines | |
| EP0799617A2 (en) | Therapeutic agent for neurological diseases | |
| SK278444B6 (en) | Substituted 5-arylpyrimidine, manufacturing process thereof and pharmaceutical composition containing its | |
| US20150299171A1 (en) | Inhibitors of bruton's tyrosine kinase | |
| US8389521B2 (en) | Inhibitors of protein kinases | |
| US8507511B2 (en) | Inhibitors of protein kinases | |
| US20080275063A1 (en) | Inhibitors of protein kinases | |
| KR20160106837A (ko) | 신규한 6-아미노-5-(치환)피리미딘-2,4(1h,3h)-디온 유도체, 이의 제조방법 및 이의 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070405 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070405 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100817 |
|
| RD13 | Notification of appointment of power of sub attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7433 Effective date: 20101116 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101117 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101125 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20101116 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20101217 |
|
| A072 | Dismissal of procedure [no reply to invitation to correct request for examination] |
Free format text: JAPANESE INTERMEDIATE CODE: A073 Effective date: 20110325 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110401 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110427 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140520 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |